ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1986

Using the BILAG to Assess the Activity of Lupus in Patients with Fibromyalgia

Robert S. Katz1, Jessica L. Polyak2 and Frank Leavitt1, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates S.C., Chicago, IL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: BILAG, fibromyalgia and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  The BILAG is often used to assess the efficacy of lupus treatments, and is a commonly used tool in lupus drug trials. But the BILAG contains many symptoms, which are also present in fibromyalgia, and the presence of concomitant fibromyalgia in lupus patients may nullify the results of clinical drug trials.  Fibromyalgia patients may not respond well to the treatment and also have more drug side effects.

Methods:  Fibromyalgia patients, meeting the 2011 ACR criteria for the diagnosis, took an in-office survey listing some of the British Isles Lupus Activity Group (BILAG) lupus symptoms. The symptoms asked of fibromyalgia and non-fibromyalgia patients included anemia; mouth or nasal sources; numbness and tingling; persistent headache; chest pain; skin rash; hair loss; cognitive changes; arthritis; and colitis. They were asked to score the above symptoms using the following scale: 1, improving; 2, same; 3, worse; and 4, new.

Results:  The following symptoms frequently represented by fibromyalgia patients and are among those that are part of BILAG Lupus Activity Index: Anemia, Headache, Rash, “Arthritis”, Oral Ulcers, Chest Pain, Hair Loss, Colitis, Numbness, and Cognitive

 

Conclusion:  Many fibromyalgia patients reported that certain symptoms that are listed in the BILAG were present including mouth and oral ulcers; hair loss; numbness and tingling; cognitive changes; headaches; arthritis; and chest pain.

Concomitant lupus and fibromyalgia can nullify the results of lupus clinical drug trials and interfere with the accurate assessment of lupus.  Many fibromyalgia patients report some of the symptoms listed in the BILAG, which is considered a reliable instrument for assessing lupus disease activity, but if the presence of concomitant fibromyalgia is not assessed, the results of the BILAG may be invalid.  Using the 2010 ACR criteria guidelines and a simple one-page form for assessing the presence of fibromyalgia, concomitant fibromyalgia can be determined in lupus patients.  This would make the BILAG a more accurate assessment tool if used for pure lupus.  

 


Disclosure: R. S. Katz, None; J. L. Polyak, None; F. Leavitt, None.

To cite this abstract in AMA style:

Katz RS, Polyak JL, Leavitt F. Using the BILAG to Assess the Activity of Lupus in Patients with Fibromyalgia [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/using-the-bilag-to-assess-the-activity-of-lupus-in-patients-with-fibromyalgia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-the-bilag-to-assess-the-activity-of-lupus-in-patients-with-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology